Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants
Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer
Multiple patients have survived substantially beyond expected median survival, including one patient who survived 28 months and several patients who remain alive with continued follow-up
SAN JOSE, Calif. , May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
ORLANDO, FL / ACCESS Newswire / May 1, 2026 / RedChip Companies will air interviews with Anixia Biosciences, Inc. (NASDAQ:ANIX) and OwlTing Group (NASDAQ:OWLS), the operating brand of OBOOK Holdings Inc.,...
Expands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative breast cancer incidence rates